Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases.

Area of Science:

• Rare disease clinical research
• Alpha-1 antitrypsin deficiency (AATD) research

Background:

• Rare diseases present unique research challenges, including limited patient populations and lack of natural history data.
• Urgent need for drug therapies and clear biomarkers for rare diseases like AATD, which often have poor prognoses.

Purpose of the Study:

• To address challenges in rare disease clinical trial design.
• To foster discussion among stakeholders including patients, researchers, industry, and regulators.
• To establish a model for rare disease clinical trial design using AATD as a case study.

Main Methods:

• Convened the 'Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases' conference.
• Facilitated discussions among key stakeholders: patients, researchers, industry, and federal regulators.
• Summarized conference discussions and conclusions regarding rare disease clinical trial design.

Main Results:

• Adaptive designs are promising for rare disease trials but require further study for feasibility in small populations.
• Natural history studies and biomarker identification are critical needs, potentially addressed through precompetitive collaborations.
• Enhanced public accessibility and integration of patient registries and databases are essential, particularly for AATD.

Conclusions:

• Further research is needed to implement adaptive trial designs effectively in rare diseases.
• Development of natural history studies and biomarkers through collaboration is vital for rare disease therapeutic advancement.
• Improved integration and public access to patient registries will accelerate rare disease research, especially for AATD.